Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Spring Bank Pharmaceuticals Awarded $3.9 Million RO1 NIH Grant to Advance Innovative Hepatitis Program

May 5, 2011 By Bio-Medicine.Org

MILFORD, Mass., May 5, 2011 /PRNewswire/ — Spring Bank
Pharmaceuticals
today announced it has been awarded an RO1
grant from the National Institute of Health, National Institute
of Allergy and Infectious Diseases
for the development of SB
9200, a novel, orally bioavailable agent for the treatment of
Hepatitis B virus infection.  

Under the terms of this award, Spring Bank Pharmaceuticals will
receive $3.9 million over five years in support of its development
efforts.  This is the fourth Federally funded grant award
Spring Bank Pharmaceuticals has received in support of it’s Small
Nucleic Acid Hybrid (SMNH) technology and brings the Company’s
total Federal support to more than $12 million.

“We are very pleased to receive this important grant award from
the NIH to further develop SB 9200 for the treatment of Hepatitis B
virus infections,” said Douglas Jensen, CEO of Spring Bank
Pharmaceuticals
. ” Hepatitis B infection is very widespread and
has proven to be a very difficult disease to treat.  The NIH
has made it clear that new types of drugs to treat Hepatitis B,
such as SB 9200, are urgently needed.”  According to R. P.
Iyer, Ph.D., Chief Scientific Officer of Spring Bank
Pharmaceuticals,
“The NIH support for our HBV program validates
our novel approach to treat this widespread disease.  SB 9200
holds great promise because it is a new class of potent orally
bioavailable drug that works by an entirely novel mechanism of
action and has demonstrated an excellent safety profile in a
battery of in vitro and in vivo toxicology studies.”

About Hepatitis B

Hepatitis B virus (“HBV”) infects roughly one-third of the
world’s population, or more than two billion people. Of these,
about 350 million become chronically infected, leading to
progressive liver disease and approximately one million deaths each
year.  Chronic infection with HBV can lead to the development
of hepatocellular

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech